Daniel De Carvalho, PhD holds the Helen M Cooke Professorship in Cancer Epigenetics, is a Scientist at the Princess Margaret Cancer Centre, and Assistant Professor at the Dept. of Medical Biophysics, University of Toronto. Dr. De Carvalho earned his PhD in Immunology from University of São Paulo in 2009 and did his postdoctoral training in Cancer epigenetics at University of Southern California (USC) at Dr. Peter Jones group from 2010 until 2012. His research focuses on understanding the molecular mechanisms driving epigenetic reprogramming in cancer and on translational aspects of cancer epigenetic therapy. De Carvalho is interested in the potential to use epigenetic therapy to improve immunotherapy in cancer and in using DNA methylation profiling of cell free DNA as a biomarker for cancer early detection and for response to therapy. Nature Medicine highlighted Dr. De Carvalho work as one of the top 10 notable advances in 2015 and by Canadian Cancer Society as one of the Top 10 Research Impact Stories of 2015. Cell, Nature Medicine, New England Journal of Medicine, and the Wall Street Journal wrote editorials about his work, highlighting the potential to improve immunotherapy using epigenetic therapy.